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Abstract
Background: Arginine vasopressin (AVP) has been hypothesized to play a role in aetiology of autism based on a
demonstrated involvement in the regulation of social behaviours. The arginine vasopressin receptor 1A gene
(AVPR1A) is widely expressed in the brain and is considered to be a key receptor for regulation of social behaviour.
Moreover, genetic variation at AVPR1A has been reported to be associated with autism. Evidence from non-human
mammals implicates variation in the 5’-flanking region of AVPR1A in variable gene expression and social behaviour.
Methods: We examined four tagging single nucleotide polymorphisms (SNPs) (rs3803107, rs1042615, rs3741865,
rs11174815) and three microsatellites (RS3, RS1 and AVR) at the AVPR1A gene for association in an autism cohort
from Ireland. Two 5’-flanking region polymorphisms in the human AVPR1A, RS3 and RS1, were also tested for their
effect on relative promoter activity.
Results: The short alleles of RS1 and the SNP rs11174815 show weak association with autism in the Irish
population (P = 0.036 and P = 0.008, respectively). Both RS1 and RS3 showed differences in relative promoter
activity by length. Shorter repeat alleles of RS1 and RS3 decreased relative promoter activity in the human
neuroblastoma cell line SH-SY5Y.
Conclusions: These aligning results can be interpreted as a functional route for this association, namely that
shorter alleles of RS1 lead to decreased AVPR1A transcription, which may proffer increased susceptibility to the
autism phenotype.
Background
The neuropeptide arginine vasopressin (AVP) has been
hypothesized to play a role in the aetiology of autism
based on a demonstrated involvement in social bonding
and in the regulation of a variety of socially relevant beha-
viours in animal models. Pharmacological experiments in
rodents have shown a role for vasopressin in learning and
memory, aggression and affiliative behaviours. Increases in
AVP are associated with stressful or defensive circum-
stances and AVP is also involved in aggressive behaviours
and pair bonding, mostly in males [1]. AVP regulates male
social behaviour not just through higher expression in
males but also in steroid-sensitive brain sexual dimorph-
isms in AVP neurons [1,2]. AVP may therefore influence
sexually dimorphic social behaviours in a range of species
[3]. The role of sex hormones on AVP is of interest in the
context of autism considering that the ratio of affected
males with autism compared to affected females is highly
skewed (4:1) [4]. Only one study has examined the rela-
tionship between AVP levels and autism; Boso et al. [5]
found AVP levels to be higher in plasma from individuals
with autism than controls (P = 0.02).
AVP acts through binding to G-protein-coupled
receptors. One of these receptors, arginine vasopressin
receptor 1A (AVPR1A), is widely expressed in the brain.
There is considerable evidence to implicate the AVPR1A
gene in social behaviours. AVPR1A-knockout mouse
models show impaired social recognition and decreased
anxiety behaviours, while overexpression of AVPR1A in
mice resulted in increased social memory [6,7]. Disrup-
tion in AVPR1A expression in the brain has been
associated with major behavioural changes [8-11].
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AVPR1A is implicated in changes in social bonding, par-
ental rearing behaviours and social recognition and
memory. Hammock and Young [12] described beha-
vioural differences in voles (genus Microtus)t h a tw a s
related back to the AVP neuropeptide. Prairie voles
(Microtus ochrogaster) are socially monogamous through
multiple breeding seasons with both the males and
females contributing to rearing of the young. These
behaviours are not typically seen within closely related
species such as the montane vole (Microtus montanus)
and meadow vole (Microtus pennsylvanicus). This phe-
nomenon has been attributed to variable expression
resulting from a microsatellite marker in the 5’-flanking
region of the AVPR1A gene in Microtus [13,14].
In humans, the 5’ region of the gene contains four repeat
elements; three promoter repeats ([GT]25,R S 1 ,( [ G A T A ] 14)
and RS3 ([CT]4TT[CT]8[GT]24)) and an intronic repeat
(AVR ([GT]14[GA]13[A]8)) (see Figure 1) [15]. These poly-
morphisms, specifically RS1 and RS3 have been studied
extensively in terms of their relationship to autism. The
data reported thus far has produced inconsistent associa-
tion with different alleles and markers implicated at this
gene. In a sample of 115 autism spectrum disorder (ASD)
proband-parent trios, Kim et al. [16] did not observe asso-
ciation for alleles of RS1 or RS3. In a smaller sample of 65
ASD trios, Wassink et al. [17] reported modest association
with a shorter allele of the RS1 polymorphism being under-
transmitted to probands with autism (max P = 0.008). This
was not confirmed in a study of 128 individuals with ASD
by Yirmiya et al. [18], where association was observed at
the AVR polymorphism (max P = 0.003). More recently,
Yang et al. [19] identified association at both RS1 and RS3
in a Korean ASD family-based study. However, the associa-
tion at the RS1 markers was not consistent with previous
findings, which may reflect population differences.
Various studies have linked different lengths of the
AVPR1A polymorphisms to behavioural traits in non-
clinical samples. Knafo et al. [20] reported that subjects
with shorter length RS3 polymorphisms were found to
be less generous by the ‘dictator game’ indicating less
altruistic behaviour [20]. Moreover, shorter variants in
general were associated with lower levels of AVPR1A
mRNA in postmortem hippocampus. Recent neuroima-
ging approaches have also indicated a link between gene
expression levels and amygdala activation [21].
Recent studies have highlighted the role of rare de novo
inherited copy number variants in the aetiology of autism
[ 2 2 ] .H o w e v e r ,o n l yr a r ede novo and inherited variants
are established as genetic risk factors, and these account
for a small proportion of the total genetic risk [23].
Furthermore, in a recent paper from the International
Schizophrenia Consortium, common genetic variants
accounted for over 30% of the genetic risk for schizo-
phrenia [24] and there is no reason to believe this will
not be the case for autism as well. The genetic factors
influencing the aetiology of autism are likely to be a com-
bination of rare, private and more common variants. The
action of which are not likely to be mutually exclusive.
Based on prior evidence suggesting a role for AVP in
human and animal social cognition, and prior reports of
genetic association between variants in vasopressin-
related genes and autism, we hypothesized that variants
in AVPR1A would be associated with autism in our Irish
autism sample. We examined the variants RS1, RS3,
AVR and four tagging single nucleotide polymorphisms
(SNPs) across the gene locus, namely rs3803107,
rs1042615, rs3741865 and rs11174815, for association
with autism in the Irish autism trio collection. Further-
more, considering the evidence to support a role
of 5’-flanking variation in the expression of AVPR1A
in Microtus, we hypothesised that variation in the 5’-
flanking region of the human AVPR1A gene at the
microsatellites’ RS3 and RS1 polymorphisms would
influence the relative effects on promoter activity.
Methods
Sample description
A total of 177 families, consisting of an affected child
and both parents were recruited through schools, parent
Figure 1 Schematic of the arginine vasopressin receptor 1A gene (AVPR1A).
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female ratio was 4.68:1. Autism diagnoses were con-
firmed using Autism Diagnostic Interview - Revised
(ADI-R) [25] and the Autism Diagnostic Observation
Schedule - Generic (ADOS-G) [26]. IQ and Vineland
Adaptive Behaviour Score (VABS) [27] were evaluated
to establish a distribution of functioning within the sam-
ple. Individuals with known medical causes of autism
(for example, tuberous sclerosis, extreme prematurity,
congenital rubella) were excluded. Subjects met the
ADI-R criteria for autism, and the ADOS-G criteria for
autism or ASD. All individuals had an IQ >35 or a men-
tal age (as defined by the VABS) >18 months. Ethical
approval was obtained from the Health Services Execu-
tive Linn Dara Child and Adolescent Psychiatry Ethics
Committee, Ireland. DNA was extracted from blood or
buccal swabs using the phenol/chloroform extraction
method.
Genotyping
Using the HapMap CEPH data, four SNPs in the
AVPR1A locus were identified using the tagger function
of Haploview [28]. SNPs were selected using pairwise
tagging with an r
2 threshold of 0.8 with an additional
2000 base pairs taken 5’ and 3’ o ft h eg e n et r a n s c r i p t .
SNP genotyping was performed by a commercial geno-
typing company, KBiosciences (http://www.kbioscience.
co.uk/) using Kaspar assays. Three additional microsatel-
lite polymorphisms (RS1, RS3, and AVR) at the AVPR1A
gene locus were also genotyped. RS1: forward (fluores-
cent) 5’-AGG GAC TGG TTC TAC AAT CTG C-3’;
reverse 5’-ACC TCT CAA GTT ATG TTG GTG G-3’.
RS3: forward (fluorescent) 5’-CCT GTA GAG ATG
TAA GTC CT-3’; reverse 5’-TCT GGA AGA GACT
TAG ATG G-3’. AVR: forward (fluorescent) 5’-ATC
CCA TGT CCG TCT GGA C-3’; reverse 5’-AGT GTT
CCT CCA AGG TGC G-3’ [15,18]. Each reaction con-
tained 0.5 mM primer. The sample was initially heated
for 10 min at 95°C followed by 30 cycles of 95°C (30 s),
55°C (30 s), 72°C (40 s) and a final extension step of
72°C for 10 min. An ABI 3130XL Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA) was used
to determine the length of each PCR product. Samples
were analysed using Genemapper v2.7 (Applied
Biosystems).
Construction of the reporter vectors
DNA samples of individuals homozygous for the RS3
variants (allele 325 and allele 339) and RS1 (allele 306
and 322) were selected from CEPH HapMap individuals.
PCR amplification of a DNA fragment containing allele
325 and allele 339 of RS3 were amplified using primers:
forward 5’-CCT GTA GAG ATG TAA GTG CT-3’;
reverse 5’ CTC GAG TCT GGA AGA GAC TTA GAT
GG-3’. For RS1, allele 306 and allele 322 were amplified
using primers: forward 5’-AGG GAC TGG TTC TAC
AAT CTG C-3’; reverse 5’-CTC GAG ACC TCT CAA
GTT ATG TTG GTG G-3’. Amplified sequences were
cloned into the pGEM-T vector (Promega, Southamp-
ton, UK). The RS3 and RS1 alleles were subcloned into
the SacIa n dXhoI site in the pGL3 control vector (Pro-
mega). The amplified promoter fragments do not con-
tain the core promoter elements of AVPR1A. Therefore,
the pGL3 control vector as opposed to the pGL3 Basic
vector was used to examine the modulating influence of
these elements as 5’-flanking polymorphism through an
SV40 promoter. Vector maps of the tested constructs
are shown in Figure 2. Sequence analysis using a BigDye
Figure 2 Vector maps of the RS3 (a) and RS1 (b) alleles subcloned into pGL3 control vector. Inserts were chosen based upon length of
polymorphism, two per polymorphism. The restriction sites used for both RS3 and RS1 were SacI and XhoI, located before the viral promoter
SV40.
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Applied Biosystems) was performed to confirm the fide-
lity and orientation of all inserts.
Cell culture and transfection
The human neuroblastoma cell line SH-SY5Y, were
maintained in RPMI 1640 containing 10% foetal bovine
serum (FBS) at 37°C and 5% CO2. Transfections were
performed in triplicate a minimum of three times using
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions.
Luciferase assay
Luciferase assays were performed using the dual-glow
luciferase system (Promega) according to the manufac-
tures’ instructions. Luminescence was measured on a
Victor plate reader (PerkinElmer, Boston, MA, USA).
Transfection efficiency was corrected for by normalising
data relative to the cotransfected renilla luciferase pRL-
cytomegalovirus (CMV) control vector (Promega). For
the RS3 and RS1 constructs, 100 ng of test constructs
were cotransfected with 500 ng pGL3 control vector.
Expression was reported as relative to the pGL3 control
vector.
Statistical analyses
Transmission disequilibrium test (TDT) for the three
microsatellites from AVPR1A were analysed in
UNPHASED [29]. Each allele is tested independently for
transmission disequilibrium. Research previously under-
taken in voles demonstrated the repeat length of the
polymorphism modified gene expression, transcriptional
pattern in the brain and social behaviours [14]. There-
fore, we decided to test for association between the
length of polymorphic repeat and autism. Alleles were
grouped in ‘long’ alleles and ‘short’ alleles for RS1, RS3
and AVR polymorphisms. Nomenclature of alleles for
RS1 and RS3 can be found in Yirmiya et al. [18]. For
RS3, ‘long’ refers to allele 327 and all repeats longer
than 327 and ‘short’ refers to allele 325 and all repeats
shorter than allele 325 consistent with the previously
published study of Knafo et al. [20]. For RS1, ‘long’ con-
sists of allele 314 and all repeats larger than allele 314
and ‘short’ consists of allele 310 and all repeats shorter
than allele 310. For AVR, ‘short’ includes allele 213 and
all repeats shorter than allele 213, while ‘long’ includes
allele 215 and all repeats larger than allele 215. A similar
procedure has been applied to other complex poly-
morphism, such as the nitric oxide synthase 1 (NOS1)
ex1f- variable number tandem repeat (VNTR) [30-33].
Hardy-Weinberg equilibrium and TDT analyses for SNP
markers were performed using PLINK [34]. TDT for
dichotomised microsatellites (long versus short) was also
performed using PLINK. No Mendelian incompatibilities
were detected and all variants were found to be in Hardy-
Weinberg equilibrium (P > 0.01) in the parents. Permuta-
tion procedures were performed in PLINK using the
mperm function (n = 1000). Haplotypes were defined
using Gabriel’s confidence intervals and tested for associa-
tion using permutation in Haploview (n = 1000) [28,35].
The statistical significance of differences in relative
gene reporter activity was examined using two-tailed
Student’s t test in Stata v. 10 (StataCorp, College Sta-
tion, TX, USA).
Power calculation
In the Irish autism sample (n = 177) at minor allele fre-
quencies of 0.20, there was greater than 80% power to
observe an effect of odds ratio (OR) approximately 1.35
at an uncorrected P = 0.05 level. This calculation con-
siders a modest effect size and also no linkage disequili-
brium between the test and causative marker.
Results
Genetic association analyses
Of the seven markers (four SNPs and three microsatel-
lite markers), only one showedas i g n i f i c a n ta s s o c i a t i o n
with autism in the Irish autism sample (rs11174815,
nominal P = 0.008). Dichotomisation of the RS1 allele
revealed a weak association of the RS1 short allele and
autism (nominal P = 0.036; odds ratio (OR) 1.44; 95%
confidence interval 1.02 to 2.04) (Tables 1 and 2). No
significant haplotype associations were observed (data
not shown).
Gene reporter assays for the RS1 and RS3 polymorphism
of AVPR1A
Differential activity was observed for alleles of both the
RS1 and RS3 variants when expressed as a luciferase
construct in the pGL3 control vector. In SH-SY5Y cells,
t h el o n gr e p e a to ft h eR S 1p o l y m o r p h i s ms h o w e d2 . 7
times higher relative activity compared to the shorter
length repeat (P = 0.0005, Student’s t test) (Figure 3).
Similarly, for the long repeat of the RS3 variant was 1.4
times more active than the short-repeat allele (P =
0.0081, Student’s t test) (Figure 3).
Discussion
In the current work we present the results of genetic
investigations of the AVPR1A gene in an Irish autism
sample. We followed association analysis with investiga-
tions to examine the role of promoter region poly-
morphisms, RS1 and RS3, on relative promoter activity.
Overall, we observed a single association with
AVPR1A in the Irish autism trio collection (rs11174815,
corrected P = 0.01). Due to the very low minor allele
frequency (minor allele frequency (MAF) = 0.015) and
lack of observations for transmissions of the A allele, it
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m a r k e ra n da u t i s mi nt h eI r i s ha u t i s ms a m p l ef r o mo u r
study. Furthermore, a weak association signal was seen
between the dichotomised RS1 polymorphism and indi-
viduals with autism in the Irish sample. The short alleles
were overtransmitted in individuals with autism.
We performed an experimental examination of the
effect of allele length of the RS1 and RS3 polymorphism
on relative promoter activity in the luciferase gene
reporter assay. For the RS1 variant we observed the
shorter allele to show lower relative promoter activity.
Previous studies have reported shorter RS1 polymorph-
isms show more activity in the left amygdala in a non-
clinical sample [36]. Excessive amygdala activation
during social interaction has been reported to be asso-
ciated with increase anxiety and eventually social with-
drawal [37]. These aligning results suggest shorter
alleles of RS1 result in lower relative promoter activity
and possibly reduced transcription of AVPR1A, increas-
ing amygdala activity leading to social withdrawal.
Shorter alleles of the RS3 polymorphism also lead to
lower relative promoter activity in the luciferase gene
reporter assay. While the RS3 polymorphism was not
shown to be associated with autism in the Irish autism
sample, it has been shown previously to be associated
with individuals with autism [17,18,38]. Knafo et al. [20]
reported individuals with shorter variants of the RS3
polymorphism have lower hippocampal AVPR1A mRNA
and shorter alleles lead to less prosocial behaviours than
longer alleles. Potentially, shorter alleles of the RS3 poly-
morphism, which show lower relative promoter activity,
lead to reduced levels of AVPR1A mRNA and lower
levels of AVPR1A in cells. Decreased levels of AVPR1A
potentially could result in less altruistic behaviours
(Table 3).
In a recent study, the human RS1 polymorphism
showed no differences in COS7 cells [39]. Furthermore,
Hong et al. [39] repeated the experiment in the PC12
cell line with no difference shown; however expression
levels were extremely low indicating a potential weak
promoter in AVPR1A. The difference in results between
this study and ours is not surprising given recent
Table 1 Genotype association results using UNPHASED
for multiallelic markers and PLINK for dichotomous
markers
Marker Allele Frequency T NT c
2 P value
RS3 305 0.001 0 1 1.00 0.32
311 0.005 2 1 0.33 0.56
319 0.001 0 1 1.00 0.32
321 0.008 3 1 1.00 0.32
323 0.058 19 16 0.26 0.61
325 0.102 31 24 0.89 0.35
327 0.214 45 36 1.00 0.32
329 0.210 43 54 1.25 0.26
331 0.099 25 26 0.02 0.89
333 0.167 44 42 0.05 0.83
335 0.026 6 11 1.47 0.23
337 0.014 4 2 0.67 0.41
339 0.059 14 20 1.06 0.30
341 0.015 4 5 0.11 0.74
343 0.017 5 6 0.09 0.76
345 0.004 2 1 0.33 0.56
Short 0.390 86 65 2.92 0.09
RS11174815 A 0.015 0 7 7.00 0.008
a 0
RS1 302 0.004 0 3 3.00 0.08
306 0.161 39 31 0.91 0.34
310 0.448 67 52 1.89 0.17
314 0.193 33 46 2.14 0.14
318 0.079 20 26 0.78 0.38
322 0.096 24 30 0.67 0.41
330 0.014 5 1 2.67 0.10
334 0.005 2 1 0.33 0.56
Short 0.518 78 54 4.36 0.036
b
RS3741865 T 0.008 2 1 0.33 0.56
RS1042615 T 0.436 55 58 0.08 0.78
AVR 204 0.002 1 0 1.00 0.32
208 0.010 2 0 2.00 0.16
210 0.108 16 21 0.68 0.41
212 0.272 43 41 0.05 0.83
214 0.461 51 48 0.09 0.76
216 0.040 10 10 0.00 1.00
218 0.006 0 1 1.00 0.32
220 0.064 10 11 0.05 0.83
222 0.001 0 1 1.00 0.32
Short 0.411 79 79 0.00 1.00
RS3803107 T 0.178 32 30 0.06 0.79
T = transmitted, NT = non-transmitted.
Associations at the suggestive a level 0.05 are shown in bold text.
aEmpirical P = 0.01.
bEmpirical P = 0.08.
Table 2 Multimarker transmission disequilibrium test
(TDT) for the microsatellite markers RS3, RS1 and AVR
reporting the likelihood ratio statistic (LRS), degrees of
freedom (df) and global P value from UNPHASED
Marker LRS df P value
RS3 10.76 15 0.769
RS1 12.22 7 0.094
AVR 8.085 8 0.425
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and cell types [40-44]. Our study examines the enhancer
effects of RS1 and RS3 in an appropriate and relevant
cell type for consideration in the aetiology of autism, a
neurological disorder. In the study undertaken here, RS1
and RS3 are examined as enhancers modulating a viral
promoter SV40 instead of its own natural promoter.
Gene reporter systems do not take into account the
genomic or chromatin context of the elements tested,
however it is encouraging that our data agree with post-
mortem mRNA levels as shown in Knafo et al. [20],
although additional studies are warranted. While the
genomic environment tested was an artificial construc-
tion without the use of the endogenous promoter, these
data do indicate that the repeat elements influence the
relative activity of a core promoter in neuronal cells.
Conclusions
The results from both RS3 and RS1 luciferase gene
reporter assays are intriguing, with potentially shorter
variants of both RS3 and RS1 leading to decreases in
AVPR1A mRNA. Our results align with the study
undertaken on the Microtus microsatellites, which
showed decreased microsatellite length contributes to
decreased sociability [13]. This suggests a potential con-
servation of function across species highlighting the
importance of these polymorphisms. However, the func-
tionality of both polymorphisms in our study compli-
cates any conclusions. A limitation of the gene reporter
approach is the removal of additional regulatory
mechanisms, which may affect the DNA region of inter-
est, and in these particular polymorphisms, how these
polymorphisms may interact with each other in the reg-
ulation of AVPR1A transcription. Our haplotype analysis
between the dichotomised alleles of RS1 and RS3
showed no association in the Irish sample. Rigorous
meta-analysis is currently not possible due to the use of
different genotyping methodologies [45]. We have used
t h es a m eg e n o t y p i n gp r i m e r sa st h eK n a f oet al. [20],
Meyer-Lindenberg et al. [21] and Levin et al. [45] allow-
ing us to draw conclusions easily across these studies.
Future work examining the regulatory relationship
between these two polymorphisms will be essential for
better understanding of how they influence in vivo tran-
scription of AVPR1A and ultimately how they poten-
tially play a role in the aetiology of autism.
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Figure 3 Relative activity of the RS3 (a) and RS1 (b) polymorphisms constructs in the neuronal SH-SY5Y cell line. (a) Longer length
repeat of the RS3 polymorphism of the arginine vasopressin receptor 1A gene (AVPR1A) showed higher relative activity compared to the shorter
length repeat of RS3 in SH-SY5Y cell lines (P = 0.0081, Student’s t test). (b) Longer length repeat of the RS1 polymorphism of AVPR1A showed
higher relative activity compared to the shorter length repeat (P = 0.0005, Student’s t test). **P < 0.01; ***P < 0.001. The graph shows the mean
of the data and standard error of the mean.
Table 3 Results from previous studies on the arginine vasopressin receptor 1A gene (AVPR1A) RS3 polymorphism
demonstrating the functionality of this region
AVPR1A RS3 repeat
length classification
Postmortem
hippocampal mRNA
levels [20]
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inhibition
[45]
Dictator game and real
money allocations [20]
Amygdala activation to
face recognition [21]
Relative transcriptional
activity (current study)
Short Down Down Down Down Down
Long Up Up (males) Up Up Up
Up/down indicate the direction of effect. Adapted from Levin et al. [45].
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